Abivax SA
2X1
Company Profile
Business description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Contact
7-11 boulevard Haussmann
Paris75009
FRAT: +33 153830963
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
67
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,552.60 | 77.00 | 0.91% |
| CAC 40 | 7,726.20 | 60.58 | 0.79% |
| DAX 40 | 22,653.86 | 273.67 | 1.22% |
| Dow JONES (US) | 46,212.10 | 634.63 | 1.39% |
| FTSE 100 | 9,894.15 | 24.18 | -0.24% |
| HKSE | 24,382.47 | 894.85 | -3.54% |
| NASDAQ | 21,950.34 | 302.72 | 1.40% |
| Nikkei 225 | 51,515.49 | 1,857.04 | -3.48% |
| NZX 50 Index | 13,002.07 | 12.08 | 0.09% |
| S&P 500 | 6,582.19 | 75.71 | 1.16% |
| S&P/ASX 200 | 8,365.90 | 82.40 | 0.99% |
| SSE Composite Index | 3,813.28 | 143.77 | -3.63% |